hepat
c
viru
hcv
thought
involv
pathogenesi
autoimmun
hepat
aih
type
defin
presenc
type
antiliv
kidney
microsom
autoantibodi
direct
mainli
cytochrom
cyp
autoreact
liver
infiltr
cell
virusspecif
cytotox
lymphocyt
ctl
recogn
infect
cell
contribut
viral
clearanc
tissu
injuri
hcv
infect
could
involv
induct
aih
explor
whether
antivir
cellular
immun
may
turn
selfantigen
character
primari
ctl
respons
hlaa
hcvderiv
epitop
ie
hcv
core
show
sequenc
homolog
human
determin
relev
homolog
pathogenesi
hcvassoci
aih
use
synthet
peptid
induc
primari
ctl
respons
peripher
blood
mononuclear
cell
healthi
blood
donor
patient
chronic
hcv
infect
found
naiv
ctl
repertoir
group
contain
crossreact
ctl
induc
hcv
peptid
recogn
peptid
well
endogen
process
protein
importantli
fail
induc
ctl
cypderiv
peptid
show
lower
capac
form
stabl
complex
molecul
find
demonstr
potenti
hcv
induc
autoreact
ctl
molecular
mimicri
possibl
contribut
virusassoci
autoimmun
utoimmun
hepat
aih
chronic
liver
diseas
unknown
etiolog
character
persist
inflammatori
reaction
liver
hallmark
aih
high
titer
serum
autoantibodi
differ
autoantigen
presenc
hepat
predominantli
mononuclear
cell
infiltr
associ
liver
cell
damag
sever
report
shown
presenc
autoreact
cell
aih
patient
liverinfiltr
cell
prolifer
respons
autolog
hepatocyt
express
high
cytolyt
activ
peripher
cell
clone
aih
patient
also
prolifer
respons
liverspecif
lipoprotein
asialoglycoprotein
receptor
type
aih
defin
presenc
type
antiliv
kidney
microsom
antibodi
recogn
cytochrom
cyp
liver
blood
patient
aih
type
autoreact
cell
recogn
detect
indic
role
cell
pathogenesi
diseas
aih
type
appear
epidemiolog
link
hepat
c
viru
hcv
infect
patient
aih
type
shown
posit
antihcv
antibodi
also
hcv
rna
suggest
hcv
may
caus
secondari
autoimmun
respons
mhc
class
irestrict
ctl
major
defens
mechan
viral
infect
suggest
ctl
respons
may
work
present
part
intern
meet
hepat
c
viru
relat
virus
venic
itali
june
contribut
viral
clearanc
well
liver
cell
injuri
hcv
infect
might
therefor
play
role
induct
autoreact
antibodi
helper
cell
ctl
recogn
endogen
process
antigen
peptid
combin
mhc
class
molecul
present
cell
surfac
sever
hcvderiv
immunogen
ctl
epitop
describ
thu
far
amino
acid
sequenc
comparison
hcvderiv
ctl
epitop
reveal
presenc
two
human
cyp
sequenc
relat
hcv
core
ie
tabl
compar
hcv
core
epitop
display
eight
amino
acid
sequenc
ident
one
conserv
substitut
nh
termin
anchor
posit
leu
val
one
nonconserv
substitut
posit
ser
val
ser
ala
cyp
sequenc
still
contain
bind
motif
leu
val
serv
anchor
residu
therefor
hcv
core
peptid
candid
molecular
mimicri
similar
infecti
agent
host
antigen
similar
may
lead
inabl
host
immun
system
recogn
foreign
antigen
may
lead
autoreact
immun
respons
level
antibodi
cell
molecular
mimicri
level
cell
seem
play
role
sever
human
autoimmun
diseas
multipl
sclerosi
rheumatoid
arthriti
myocard
herp
stromal
kerat
report
describ
possibl
molecular
mimicri
level
cell
also
publish
determin
relev
sequenc
similar
hcvderiv
ctl
epitop
member
cyp
famili
pathogenesi
hcvassoci
autoimmun
hepat
analyz
primari
ctl
repertoir
induc
primari
ctl
respons
pbmc
hcvneg
healthi
blood
donor
well
patient
chronic
hcv
infect
without
marker
aih
induct
use
hcv
core
epitop
well
cypderiv
peptid
ctl
test
abil
recogn
three
differ
peptid
ligand
studi
popul
healthi
individu
patient
chronic
hepat
c
studi
sampl
patient
chronic
hcv
infect
obtain
least
mo
diagnosi
hcv
infect
patient
repeatedli
test
posit
antihcv
antibodi
one
except
hcv
rna
detect
pcr
patient
treat
sampl
collect
two
patient
finish
ineffect
treatment
sampl
collect
none
hcv
patient
test
posit
autoimmun
hepat
serum
marker
patient
healthi
blood
donor
neg
antibodi
hiv
hbv
healthi
donor
also
neg
antihcv
antibodi
cell
line
ebvtransform
b
cell
line
jy
hlaa
cell
cultur
rpmi
medium
supplement
l
glutamin
mm
penicillin
uml
streptomycin
gml
hepe
mm
contain
volvol
heatinactiv
fc
fcsmedium
human
b
lymphoblastoid
cell
line
tk
deriv
rpmi
cell
line
hla
type
maintain
fcsmedium
cell
tk
cell
transfect
vector
code
human
respect
refer
cultur
select
rpmi
medium
mm
l
histidinol
without
l
histidin
gentest
corp
supplement
l
glutamin
mm
penicillin
uml
streptomycin
gml
hepe
mm
contain
volvol
heatinactiv
fc
tk
cell
gift
charl
l
crespi
gentest
corp
woburn
induct
primari
ctl
pbmc
healthi
donor
hcv
patient
isol
ficollpaqu
densiti
gradient
wash
three
time
pb
contain
fcsmedium
pbmc
incub
synthet
peptid
gml
chiron
mimotop
rpmi
medium
supplement
l
glutamin
mm
penicillin
uml
streptomycin
gml
hepe
mm
contain
volvol
heatinactiv
human
ab
serum
abmedium
h
wash
pb
contain
fcsmedium
plate
plate
cellswel
abmedium
day
weekli
thereaft
ml
complet
medium
supplement
uml
eurocetu
bv
ad
well
day
weekli
thereaft
cultur
restimul
peptidepuls
irradi
rad
autolog
feeder
cell
ml
abmedium
contain
uml
cultur
pbmc
test
ctl
activ
differ
peptid
day
gener
peptidespecif
cell
line
peptidespecif
induct
cultur
deplet
cell
use
neg
select
accord
manufactur
instruct
dynabead
dynal
plate
cell
per
well
plate
cell
plate
fcsmedium
presenc
pha
gml
uml
irradi
rad
allogen
pbmc
cell
ml
irradi
rad
peptidepuls
gml
h
jy
ebvb
cell
cellsml
peptidespecif
well
expand
restimul
plate
describ
cytotox
assay
jy
target
cell
incub
synthet
peptid
gml
fcsmedium
overnight
target
cell
peptidepuls
jy
cell
tk
deriv
cell
label
ci
na
cr
amersham
pharmacia
biotech
h
wash
four
time
pb
contain
fcsmedium
cytolyt
activ
determin
standard
crreleas
assay
use
ubottom
plate
contain
target
per
well
indic
figur
legend
cell
per
well
ad
reduc
unspecif
lysi
percentag
cytotox
determin
formula
experiment
releas
spontan
releas
maximum
releas
spontan
releas
maximum
releas
determin
lysi
target
hcl
spontan
releas
maxim
releas
assay
specif
lysi
calcul
differ
lysi
target
peptid
plasmid
target
without
peptid
plasmid
peptid
titrat
experi
jy
target
cell
incub
variou
peptid
concentr
min
cr
label
wash
pb
use
describ
function
mhc
bind
assay
jy
target
cell
puls
synthet
peptid
min
indic
time
assay
wash
twice
pb
contain
fcsmedium
incub
fcsmedium
cr
label
use
describ
depend
target
recognit
test
addit
gml
antibodi
ortho
diagnost
system
inc
cytotox
assay
peptid
strip
mild
acid
treatment
jy
cell
wash
twice
pb
put
ice
min
cell
treat
ml
icecold
citric
acidna
hpo
buffer
mixtur
equal
volum
citric
acid
na
hpo
ph
immedi
thereaft
elut
cell
buffer
cold
imdm
wash
imdm
resuspend
cell
imdm
gml
microglobulin
sigma
chemic
co
competitionbas
mhc
class
peptid
bind
assay
peptid
test
bind
affin
use
previous
describ
peptid
bind
assay
brief
cell
strip
see
resuspend
cellsml
imdm
plu
gml
microglobulin
fluorescein
fl
label
refer
peptid
flpsdc
fl
fpsv
l
end
concentr
nm
incub
l
competitor
peptid
differ
end
concentr
vbottom
plate
l
mild
acidtr
jy
cell
ad
well
mixtur
incub
h
c
wash
twice
pb
contain
bsa
resuspend
contain
paraformaldehyd
analyz
facscan
becton
dickinson
mean
fluoresc
mf
valu
obtain
well
without
competitor
peptid
regard
maxim
bind
equat
inhibit
mf
obtain
well
without
refer
peptid
equat
inhibit
percentag
inhibit
bind
calcul
use
formula
mf
nm
refer
competitor
peptid
mf
refer
peptid
mf
nm
refer
peptid
mf
refer
peptid
measur
mhcpeptid
complex
stabil
jy
cell
concentr
cellsml
incub
emetin
sigma
chemic
co
h
c
stop
protein
synthesi
subsequ
emerg
de
novo
synthes
class
molecul
cell
surfac
cell
wash
twice
pb
peptid
strip
see
cell
ad
g
peptid
ml
incub
min
room
temperatur
cell
wash
twice
icecold
imdm
resuspend
ml
imdm
subsequ
cell
incub
h
c
thereaft
stain
confirmationspecif
mab
goat
antimous
fitc
thereaft
cell
fix
resuspens
contain
paraformaldehyd
analyz
facscan
fluoresc
index
fi
calcul
fi
mean
fluoresc
sampl
mean
fluoresc
background
mean
fluoresc
background
without
peptid
sampl
test
duplic
variat
sampl
alway
stabil
character
bind
properti
hcv
core
homolog
cyp
peptid
determin
affin
stabil
form
complex
hcv
core
bound
intermedi
affin
previous
describ
wherea
cyp
peptid
bound
low
affin
fig
similar
result
obtain
measur
peptideinduc
stabil
molecul
surfac
transporterassoci
antigen
processingdefici
cell
data
shown
determin
mhcpeptid
complex
stabil
show
hcv
core
peptid
abl
form
stabl
complex
halflif
h
well
peptid
dissoci
much
faster
halfliv
h
fig
b
induct
primari
ctl
determin
effect
differ
bind
properti
cell
activ
antigen
recognit
ctl
first
analyz
naiv
ctl
repertoir
healthi
blood
donor
pbmc
healthi
hcvseroneg
blood
donor
stimul
synthet
hcv
core
peptid
four
replica
cultur
wk
cultur
test
ctl
activ
target
cell
present
three
peptid
longterm
stimul
hcv
core
peptid
induc
hcv
core
ctl
nine
hcvseroneg
blood
donor
tabl
ii
five
individu
hcv
core
ctl
recogn
induc
hcv
peptid
also
andor
selfpeptid
higher
specif
lysi
target
present
observ
case
two
donor
recogn
three
peptid
three
individu
recogn
hcv
core
four
recogn
hcv
core
three
show
ctl
respons
stimul
hcv
core
repres
result
three
donor
shown
fig
result
well
data
obtain
ctl
line
deriv
posit
cultur
data
shown
indic
presenc
three
phenotyp
hcv
core
ctl
ctl
recogn
hcv
core
ctl
crossreact
hcv
core
ctl
specif
hcv
core
find
ctl
recogn
without
recognit
cell
recogn
one
cyp
peptid
without
recognit
hcv
core
importantli
ctl
respons
could
induc
selfpeptid
fig
b
fig
c
donor
test
fit
observ
differ
mhcpeptid
interact
peptideinduc
mhc
stabil
immunogen
peptid
strongli
correl
strategi
use
analyz
hcv
core
ctl
repertoir
patient
chronic
hcv
infect
without
marker
aih
percentag
patient
crossreact
ctl
compar
healthi
donor
tabl
ii
suggest
peripher
pool
naiv
ctl
specif
hcv
core
compar
one
uninfect
individu
precursor
frequenc
crossreact
ctl
similar
astonish
chronic
hcv
infect
associ
low
number
ctl
peripher
blood
peptid
recognit
crossreact
ctl
line
hcv
core
ctl
line
deriv
donor
use
test
biolog
function
peptid
cytotox
assay
despit
differ
mhc
bind
affin
abil
hcv
core
hcv
core
hcv
core
none
number
percentag
individu
recogn
indic
peptid
primari
induct
hcv
core
ctl
respons
specif
lysi
et
ratio
primari
induct
cultur
consid
posit
one
patient
posit
accord
criteria
mention
cell
line
could
establish
limit
dilut
stabil
mhc
complex
three
peptid
recogn
ctl
effici
fig
higher
offrat
cyp
peptid
effect
ctl
recognit
peptidepuls
target
cell
incub
without
peptid
h
exposur
ctl
fig
b
explan
phenomenon
could
depend
target
recognit
although
lysi
target
cell
present
hcv
core
markedli
reduc
antibodi
recognit
less
affect
effect
recognit
fig
c
find
unexpect
similar
find
observ
alramadi
et
al
demonstr
pattern
function
activ
variant
peptid
alway
correl
mhc
bind
fact
mechan
involv
interact
ctl
target
cell
may
import
tcr
affin
mhcpeptidecomplex
bind
mhc
class
well
costimulatori
cell
adhes
molecul
assess
role
bind
ctltarget
cell
interact
use
panel
three
differ
antibodi
test
effect
target
cell
lysi
repres
experi
shown
fig
c
use
antibodi
although
recognit
hcv
core
depend
part
avail
selfpeptid
recognit
studi
requir
defin
mechan
respons
discrep
observ
peptidemhc
bind
ctlmediat
cytotox
recognit
endogen
synthes
antigen
abil
hcv
core
ctl
recogn
endogen
synthes
antigen
studi
use
tk
cell
line
transfect
cell
transfect
unrel
target
cell
cytotox
assay
kill
cell
ctl
line
donor
higher
lysi
parent
cell
line
tk
control
cell
transfect
fig
suggest
natur
process
peptid
gener
proteolyt
machineri
present
molecul
hcv
core
peptid
describ
target
epitop
ctl
present
peripher
blood
patient
chronic
hcv
infect
peptid
process
present
via
endogen
mhc
class
pathway
use
pbmc
healthi
hcvseroneg
individu
well
patient
chronic
hcv
infect
induc
primari
ctl
respons
epitop
two
homolog
cypderiv
peptid
ctl
induc
hcv
core
peptid
recogn
induc
hcv
peptid
also
show
autoreact
lyse
target
present
cypderiv
selfpeptid
target
cell
stabli
transfect
plasmid
code
whole
protein
show
cyp
epitop
also
present
via
endogen
mhc
class
pathway
among
ctl
could
distinguish
three
differ
function
type
individu
cell
recogn
hcv
core
cell
crossreact
hcv
core
cell
recogn
hcv
core
cyp
epitop
indic
polyclon
respons
hcv
core
distinct
hierarchi
induct
selfreact
ctl
viral
epitop
compat
molecular
mimicri
resembl
pathogen
host
antigen
mechan
describ
mainli
level
antibodi
cell
molecular
mimicri
level
cell
implic
human
autoimmun
diseas
multipl
sclerosi
rheumatoid
arthriti
myocard
well
herp
stromal
kerat
recent
studi
also
describ
crossreact
cell
specif
myelinderiv
peptid
saccharomyc
cerevisia
peptid
case
crossreact
ctl
could
induc
selfpeptid
saccharomyc
antigen
studi
could
induc
ctl
cypderiv
selfpeptid
although
selfpeptid
rec
ogniz
ctl
induc
hcv
core
epitop
indic
differ
cell
activ
properti
selfepitop
compar
hcv
peptid
describ
alter
peptid
ligand
apl
analogu
immunogen
peptid
amino
acid
substitut
induc
differ
effect
ctl
apl
act
agonist
lead
full
activ
cell
partial
agonist
induc
reduc
cell
respons
even
antagonist
inhibit
respons
unalt
immunogen
epitop
molecular
mechan
aplinduc
partial
cell
activ
still
matter
debat
complex
nativ
ligand
apl
mhc
molecul
bind
tcr
induc
differ
intracellular
signal
cell
either
differ
oligomer
necessari
molecul
molecul
failur
apl
induc
requir
conform
chang
tcr
studi
state
level
cell
activ
depend
number
tcr
trigger
process
serial
engag
mani
tcr
peptidemhc
complex
allow
singl
ctl
gener
differ
biolog
respons
although
specif
cytotox
alreadi
detect
low
peptid
concentr
product
prolifer
requir
higher
concentr
correspond
higher
number
tcr
trigger
accord
find
immunogen
antigen
peptid
strongli
correl
stabil
mhcpeptid
complex
form
indic
high
number
high
stabil
mhcpeptid
complex
essenti
trigger
suffici
number
tcr
fulli
activ
naiv
cell
despit
final
effect
affin
differ
kinet
chang
multimolecular
interact
antigen
recognit
predict
strict
correl
function
activ
variou
peptid
mhc
bind
effici
affin
mhcpeptid
complex
tcr
shown
signal
induc
unstabl
complex
cypderiv
selfpeptid
suffici
activ
naiv
ctl
way
evid
cyp
peptid
neither
induc
neg
select
thymic
develop
lead
anergi
detect
crossreact
ctl
precursor
peripher
blood
hand
hcv
core
peptid
form
stabl
mhcpeptid
complex
abl
induc
full
activ
includ
matur
ctl
activ
crossreact
ctl
cytolyt
function
induc
hcv
peptid
also
cypderiv
apl
cytotox
requir
lower
threshold
activ
prolifer
activ
subpopul
crossreact
ctl
show
differ
recognit
three
peptid
ligand
recogn
hcv
core
cyp
peptid
similar
peptid
concentr
found
clinic
observ
hcv
infect
preced
develop
aih
accord
hypothesi
antivir
immun
respons
predat
autoimmun
moreov
presenc
autoreact
cell
blood
liver
aih
type
patient
demonstr
indic
role
cell
pathogenesi
diseas
crossreact
ctl
may
contribut
liver
cell
damag
lysi
infect
uninfect
hepatocyt
ongo
viral
infect
lysi
uninfect
autoantigenexpress
hepatocyt
viral
clearanc
howev
presenc
virusinduc
autoreact
ctl
alon
suffici
lead
typic
aih
none
test
hcv
patient
marker
aih
autoantibodi
probabl
presenc
autoreact
well
autoreact
helper
cell
requir
induct
aih
antigen
specif
cell
detect
aih
patient
would
need
activ
b
cell
secret
aih
marker
autoantibodi
furthermor
autoreact
cell
could
maintain
autoreact
cell
respons
viral
clearanc
compar
chronic
viral
infect
cell
essenti
maintain
ctl
respons
summari
sever
argument
underscor
biolog
relev
find
first
viral
epitop
well
selfepitop
natur
process
present
human
host
cell
second
selfepitop
viral
epitop
coexpress
coloc
liver
natur
hcv
infect
express
even
enhanc
hcvinfect
liver
third
absenc
cypinduc
ctl
peripher
blood
suggest
central
peripher
toler
mechan
oper
indic
selfepitop
present
cell
vivo
fourth
data
present
show
high
level
crossrecognit
viral
induc
ctl
selfpeptid
suggest
mediat
liver
cell
damag
uninfect
cell
fifth
anoth
line
evid
link
hcv
infect
autoimmun
hepat
type
diseas
describ
occur
subsequ
hcv
infect
interestingli
associ
typic
associ
presenc
autoantibodi
direct
cytochrom
well
autoreact
cell
suggest
parallel
occurr
autoreact
cytochrom
level
b
cell
hypothes
liver
cell
damag
mediat
virusspecif
ctl
lead
releas
intracellular
protein
like
uptak
autoantigen
profession
apc
autoantibodi
format
presenc
autoreact
b
cell
viral
clearanc
autoimmun
diseas
upheld
ongo
hepatocyt
lysi
crossreact
hcvinduc
ctl
maintain
autoreact
helper
cell
coincid
hcv
autoreact
b
cell
autoreact
cell
thu
requir
induct
hcvassoci
aih
would
explain
rel
low
frequenc
aih
among
hcv
patient
despit
high
number
individu
crossreact
ctl
find
demonstr
potenti
hcv
induc
autoreact
ctl
molecular
mimicri
core
protein
therefor
show
possibl
mechan
hcv
may
trigger
aih
studi
analyz
crossreact
pattern
hcv
corespecif
ctl
deriv
untreat
patient
activ
hcvassoci
autoimmun
hepat
requir
order
establish
mechan
